AOD-9604 and HGH Fragment 176-191 are chemical cousins drawn from the same C-terminal tail of human growth hormone, not two trade names for one substance. The distinction decides which evidence file applies: AOD-9604 is the version that went through formal drug development and randomised human trials, while the fragment sold most widely as a fat-loss peptide has no comparable human efficacy record of its own. Neither is an approved medicine for weight loss in any major jurisdiction, and both are prohibited at all times in sport.
| Criterion | HGH Fragment 176-191 | AOD-9604 |
|---|---|---|
| Sequence | Residues 176 to 191 of the 191-amino-acid hormone | Tyr-hGH(177-191), tyrosine added at the N-terminus |
| Human efficacy trials | None published | Randomised placebo-controlled obesity trials |
| Development status | Never a formal drug candidate | Obesity development discontinued |
| Market channel | Research-chemical supply, unverified identity | Research-chemical supply, unverified identity |
AOD-9604 is Tyr-hGH(177-191), a tyrosine-tagged analogue of the 177 to 191 stretch, while HGH Fragment 176-191 is the unmodified sixteen-residue C-terminal sequence, and only AOD-9604 carries a published randomised controlled human trial record.
Almost all of the sequence is shared, and a single added residue is the whole difference. Both peptides come off the C-terminal end of the same 191-amino-acid chain and both keep the Cys182 to Cys189 disulfide loop credited with holding that region in the conformation associated with its reported metabolic activity. That one residue is small on paper and decisive in the laboratory, which is why a catalogue quoting one molecular weight for both names is describing something that cannot be true of both.
The tyrosine on AOD-9604 carries an aromatic phenol side chain that changes mass, changes ultraviolet absorbance and provides a radioiodination site, which is why regulators, patent examiners and anti-doping laboratories have treated the two peptides as distinct chemical entities throughout their histories.
The tyrosine was never a performance feature. Iodination chemistry needs an aromatic residue and the native C-terminal stretch does not carry one, so the tag was added to let the Monash and Metabolic Pharmaceuticals researchers track distribution, clearance and receptor interaction in animals. What kept it there afterwards was ownership, because a naked fragment of an endogenous human hormone is difficult to claim as a novel composition of matter and a defined analogue is not.
The N-terminal tyrosine was added for radiolabelling rather than potency, and it left the rapid clearance and poor oral bioavailability of the C-terminal peptide unchanged; what it bought was traceability, a defensible patent estate and a single defined clinical candidate.
The rodent literature cited for both peptides traces back to largely the same research lineage, which is exactly why the two look interchangeable at the preclinical level and exactly why that impression is unreliable. The founding observation was that the C-terminal region kept growth hormone's ability to break down stored fat and to suppress the conversion of carbohydrate to fat in adipose tissue, apparently without the growth-promoting and insulin-antagonising activity carried by other parts of the molecule.
| Preclinical criterion | HGH Fragment 176-191 | AOD-9604 |
|---|---|---|
| Reported ob/ob mouse effect | Reduced weight gain, increased fat oxidation over roughly two weeks | Same effect profile inside the developer's programme |
| Proposed mechanism | Increased adipose beta-3 adrenergic receptor expression | Increased adipose beta-3 adrenergic receptor expression |
| Human relevance of that mechanism | Weak: adult human fat expresses far fewer beta-3 receptors than rodent fat | Weak, and the failed human trials later matched that reading |
| In vitro adipocyte data | No uniformly consistent picture of potency or dose response | No uniformly consistent picture of potency or dose response |
Neither rodent dataset can stand in for the other, because head-to-head experiments comparing the exact 176-191 fragment against AOD-9604 in the same model are scarce and independent replication outside the originating group has been limited.
This is where the two compounds separate hardest, and where consumer material blurs them most. AOD-9604 went into randomised double-blind placebo-controlled studies in overweight and obese adults, and the encouraging early result did not survive the larger and longer follow-up. None of that record belongs to the unmodified fragment, since the ordinary scientific standard attaches a clinical result to the exact molecule, dose and route studied.
Tolerability across the AOD-9604 trials was generally unremarkable, but the programme ended in a properly powered failure to separate from placebo on its primary weight endpoint, and the unmodified 176-191 fragment has no published randomised controlled human efficacy trial at all.
On this narrow point the record has been reasonably consistent: the reported animal work and the human AOD-9604 studies did not show meaningful IGF-1 elevation or the fall in insulin sensitivity and rise in fasting glucose that can follow supraphysiological growth hormone exposure. Growth hormone raises IGF-1 through receptor binding sites that sit outside the 176-191 tail, so a short C-terminal peptide would not be expected to trigger that cascade. What none of this supports is the marketing line that these peptides deliver the fat-loss benefit of growth hormone with none of its risks, because IGF-1 mediates much of what the hormone actually does.
The absence of an IGF-1 rise is a statement about mechanism rather than a safety guarantee, since monitored human exposure to AOD-9604 was measured in weeks to months with defined material and the unmodified fragment has no monitored human safety dataset at all.
They barely differ, and neither classification works in the buyer's favour. No major regulator in the United States, the European Union or Australia has approved either compound for obesity or body composition, and both sit in the World Anti-Doping Agency's category for non-approved substances, prohibited at all times, in and out of competition.
The self-affirmed generally recognised as safe determination made for AOD-9604 in a narrow food ingredient context has no efficacy component and is not drug approval, and the prohibition on non-approved substances in sport applies to both peptides at all times regardless of that footnote.
A large share of the promotional copy written about HGH Fragment 176-191 rests on citations that, once opened, turn out to describe AOD-9604. The tell is consistent, and it sits in the vocabulary of the claim rather than in the footnote. The most damaging borrowing is selective, since what gets left out of the citation does more work than what gets cited.
A paper whose methods section names Tyr-hGH(177-191) or AOD9604 is not evidence for HGH Fragment 176-191, and that single substitution accounts for essentially every human-sounding claim made for the fragment in consumer marketing.
When a catalogue lists both names as one product, quotes a single molecular weight for both, or describes the fragment using AOD-9604's clinical history, it is describing a category rather than a characterised substance. Buyers in that position have no reliable way of establishing which molecule, if either, is in the vial, and no external body is verifying the answer.
Interchangeable naming is why the informal evidence base around these peptides cannot be assembled into anything meaningful, because neither the identity of the material nor the molecule behind any given user report can be established.
Educational use only. This article describes what the published scientific and clinical literature reports about HGH Fragment 176-191 and AOD-9604. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
